Search

Displaying results 3691 - 3700 of 5419 in total
  1. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide der...

  2. Drug

    Tilorone

    go.drugbank.com/drugs/DB17965
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  4. Drug

    Gossypol

    go.drugbank.com/drugs/DB13044
    Investigational

    Gossypol has been used in trials studying the treatment of Non-small Cell Lung Cancer.

    Categories: Hormonal Contraceptives for Systemic Use
  5. Drug

    Cefetamet

    go.drugbank.com/drugs/DB13504
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Propicillin

    go.drugbank.com/drugs/DB13660
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family.

  8. Drug

    Sea salt

    go.drugbank.com/drugs/DB11266
    Approved

    Sea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.”

    Synonyms: bay salt
  9. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

  10. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    On August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.